Discussions with leaders: Johannes Czernin talks with Mike Sathekge, a nuclear medicine leader in South Africa, about challenges and promise for nuclear medicine practice and technology in Africa . . . . . ***Page 593***

PSMA PET for prostate cancer: Farolfi and colleagues provide a state-of-the-art overview of the latest literature on current and emerging indications for prostate-specific membrane antigen PET imaging, as well as recommended interpretation criteria . . . . . ***Page 596***

Evaluation of biomarker cut points: Polley and Dignam review common statistical issues related to biomarker cut point identification and offer guidance on proper evaluation, interpretation, and validation . . . . . ***Page 605***

Tau and cognition: Tanner and Rabinovici look at tau imaging for in vivo visualization of molecular pathology in Alzheimer disease and at enhanced precision medicine approaches enabled by correlation of imaging with cognitive status and clinical severity . . . . . ***Page 612***

Understanding tau positivity: Villemagne and colleagues survey available evidence for and potential alternatives to establishing tau positivity, with a goal of consensus on normal and abnormal tau imaging values for implementation in clinical research and therapeutic trials . . . . . ***Page 614***

^{99m}Tc-Tilmanocept and SLN biopsy: Vidal-Sicart and colleagues describe multi-institutional results with ^{99m}Tc-tilmanocept in a heterogeneous group of breast cancer patients undergoing varied protocols for sentinel lymph node biopsy . . . . . ***Page 620***

^{18}F-FLT PET/CT in lung cancer relapse: Christensen and colleagues investigate the value added by ^{18}F-FLT PET/CT to ^{18}F-FDG PET/CT in diagnosis of relapse after definitive radiotherapy in patients with lung cancer . . . . . ***Page 628***

^{18}F-FES PET in endometrial cancer: Yamada and colleagues evaluate the potential of 16α-^{18}F-fluoro-17β-estradiol PET for predicting outcomes and possibly guiding treatment in patients with endometrial cancer and compare these results with those from ^{18}F-FDG PET/CT . . . . . ***Page 636***

PET/CT in UrC-ADC: Das and colleagues report on the effect of ^{18}F-FDG PET/CT on management of patients with urachal adenocarcinoma, with a focus on identification of metastatic disease not appreciated on anatomic imaging . . . . . ***Page 643***

PAMI and lymph node metastasis: Nishio and colleagues assess photoacoustic molecular imaging of panitumumab, conjugated to a near-infrared fluorescent dye, for identification of occult metastatic lymph nodes in head and neck squamous cell carcinoma . . . . . ***Page 648***

Imaging therapeutic modulation of PD-L1: Jung and colleagues detail the development of an ^{89}Zr-labeled anti–programmed death ligand 1 immune PET tracer that can monitor chemotherapy-mediated modulation of tumor PD-L1 expression in living subjects . . . . . ***Page 656***

^{11}C-PS13 for COX-1 imaging in cancer: Boyle and colleagues consider the repurposing of ^{11}C-PS13, a cyclooxygenase-1 PET neuroimaging radiopharmaceutical, in an ovarian cancer–xenografted mouse model . . . . . ***Page 665***

^{225}Ac-PSMA I&T for mCRPC: Zacherl and colleagues detail clinical data on patients with advanced metastatic castration-resistant prostate cancer who underwent both imaging and targeted α-therapy with ^{225}Ac-prostate-specific membrane antigen . . . . . ***Page 669***

PSMA PET in PCWG3: Farolfi and colleagues assess the screening impact of prostate-specific membrane antigen PET on the Prostate Cancer Clinical Trials Working Group 3 clinical subtype classification for castration-resistant prostate cancer when compared with conventional imaging. . . . . ***Page 675***

^{18}F-rhPSMA-7.3 dosimetry: Tolvanen and colleagues report on a first-in-humans study of the safety, biodistribution, and radiation dosimetry of this novel ^{18}F-labeled radiohybrid prostate-specific membrane antigen PET imaging agent. . . . . ***Page 679***

MIBG and neuroendocrine tumors: Yoshinaga and colleagues describe the effects of repeated ^{131}I-meta-iodobenzylguanidine therapy on tumor size and tumor metabolic response in patients with metastatic neuroendocrine tumors . . . . . ***Page 685***

Prostate cancer, PET, and disparities: Bucknor and colleagues investigate potential differences in imaging access for patients receiving ^{18}F-fluciclovine or ^{68}Ga-prostate-specific membrane antigen for biochemically recurrent prostate cancer at a tertiary medical center . . . . . ***Page 695***

BAT radiomic repeatability: Nazeri and colleagues explore the repeatability of activated brown adipose tissue radiomic features on imaging as well as the impact of reconstruction methods and imaging modality choice . . . . . ***Page 700***

PET radiomic feature repeatability: Crandall and colleagues assess the test–retest repeatability of radiomic features extracted from ^{18}F-FDG PET images of cervical tumors and explore the effects of different image preprocessing methods . . . . . ***Page 707***

Absolute ^{99m}Tc-pyrophosphate quantitation: Dorbala and colleagues determine correlations between absolute quantitative ^{99m}Tc-pyrophosphate metrics using a novel SPECT/CT system and traditional measures of cardiac amyloid burden and also assess intraobserver repeatability of the quantitative metrics . . . . . ***Page 716***

(±)-^{11}C-YJH08 PET and GR expression: Huang and colleagues report on basic and preclinical studies with this novel PET tracer targeted at measuring glucocorticoid receptor expression . . . . . ***Page 723***

PET quantitative bias in vivo: Lodge and colleagues use data acquired from patient volunteers to characterize bias in underlying PET imaging data, with results that provide additional support for use of quantitative imaging biomarkers . . . . . ***Page 732***

Fast total-body PET parametric imaging: Feng and colleagues describe a method to acquire whole-body ^{18}F-FDG PET parametric images using only the first 90 seconds of postinjection scan data from a recently developed total-body PET system . . . . . ***Page 738***